Phase 1 Clinical Trials: A Look into the Future

New Horizons in the Global Clinical Research Ecosystem: Technological Transformation, Data Analytics, and the 2026 Vision

Drug and medical device development processes are experiencing one of the most rapid and complex transformation periods in human history. Phase 1 clinical trials, which were previously evaluated only as a safety threshold, have today become the epicenter of precision medicine applications, advanced data analytics, and biotechnological innovation. Projections for 2026 indicate that digitalization, artificial intelligence (AI), and decentralized models (DCT) in clinical trial design will be an integral part of standard operational procedures. Turkey, particularly through institutions like the İzmir MedicalPoint Prof. Dr. Ahmet Uğur Yılmaz Clinical Research Center, is positioned as a strategic node in this global ecosystem.

The Evolution of Clinical Research: Transition from Traditional Methodology to Smart Designs

The discipline of clinical research combines the fundamental principle of “do no harm” with the speed and precision offered by modern technology. While traditional Phase 1 studies focus on determining the pharmacokinetic and pharmacodynamic properties of a drug in a small group of volunteers (usually 20-80 people), modern approaches bring this process even earlier with “Phase 0” or “microdose” studies, supported by AI-powered simulations. The primary motivation for this transformation is to optimize the time and cost for a drug candidate to reach the market from the laboratory. In this process, which traditionally lasts 10-12 years and costs billions of dollars, the Phase 1 stage has now turned into a critical data mine where “proof-of-mechanism” data is provided at the earliest stage.

The Biotechnological Revolution and the Dominance of mRNA Platforms

The pandemic process has proven that mRNA technology is not only a vaccine platform but also a versatile therapeutic tool. The years 2025 and 2026 are recorded as a period where mRNA-based treatments exploded in the fields of oncology, rare diseases, and metabolic disorders. mRNA platforms offer significant advantages over traditional viral vector or plasmid DNA systems due to their non-integration into the host genome and rapid production capacities. Particularly in oncology, Phase 1 trials where personalized “neoantigen” vaccines are designed based on the patient’s tumor biopsy, combined with immunotherapy, are opening a new era in cancer treatment. Looking at the global distribution of mRNA clinical trials, it is observed that as of 2025, a large portion of the 557 registered active trials are concentrated in Phase 0-1 stages. This situation shows that the technology is still in the maturation stage but is progressing with great speed.

mRNA Clinical Trial Data and Projections

Operational Impact of Artificial Intelligence (AI) and Machine Learning

2026 is a turning point where artificial intelligence in clinical research transitioned from the “experiment” phase to the “application” phase. AI-supported protocol automation increases data quality and accelerates schedules by minimizing manual processes. Specifically, generative artificial intelligence (GenAI) shortens the time for drafting complex clinical protocols, personalizing patient informed consent forms, and preparing regulatory documentation by 30%. Analyses by organizations such as McKinsey and IQVIA reveal that AI-supported processes have a savings potential of 60 to 110 billion dollars annually in biopharma R&D productivity. It is calculated that a 12-month time saving in a clinical development program provides a net value increase of more than 400 million dollars at the portfolio level.

In Silico Clinical Trials: Virtual Patients and Digital Twins

One of the most striking innovations in the field of clinical research is “In Silico” clinical trials (ISCT). This approach allows trials to be conducted on virtual patients through mathematical models and computer simulations before testing on real humans or to support these tests. This method radically changes the dose-finding process, especially in Phase 1 trials.

Mathematical Foundations of Pharmacokinetic and Pharmacodynamic Modeling

In silico models use non-linear mixed-effects models (NLME) and physiologically based pharmacokinetic models (PBPK) to predict pharmacokinetic (PK) parameters that express a drug’s distribution in the body. A drug’s plasma concentration, $C(t)$, is generally simulated with differential equations such as the following:

$$\frac{dC}{dt} = \frac{k_a \cdot D \cdot F}{V_d} \cdot e^{-k_a \cdot t} – k_e \cdot C(t)$$

In this equation:

• D: Dose
• F: Bioavailability
• Vd: Volume of distribution
• ka: Absorption constant
• ke: Elimination constant

Simulations using virtual patients maximize “first dose” safety in Phase 1 trials by allowing us to foresee the inter-individual variability of these parameters.

In Silico Impact on Time and Cost Savings

Case studies from pioneering companies like Insilico Medicine show that AI and simulation platforms have reduced the time to move a drug candidate from the preclinical stage to Phase 1 from the traditional 4.5 years to 18 months. This acceleration means a reduction in costs by up to 90%.

Comparison of Traditional and AI-Supported Development

Decentralized Clinical Trials (DCT) and Hybrid Designs

In traditional clinical trial models, the constant physical visit of patients to specific centers is the biggest logistical obstacle to participation. In 2026, it is observed that decentralized (DCT) or hybrid models have become dominant, including in Phase 1 trials. The DCT approach integrates digital health technologies (DHT) such as telemedicine, wearable sensors, e-Consent, and direct-to-patient drug delivery, incorporating the research into the patient’s daily life.

Remote Monitoring and Data Integrity

Wearable devices have the potential to monitor Phase 1 volunteers’ vital signs 24/7, catching momentary adverse events that might be missed during center visits. For example, in a Phase 1 PK study conducted with centanafadine, it was recorded that vital signs were successfully collected at 75%, ECG data at 80%, and blood micro-samples at 65-70% through remote monitoring platforms. This situation proves the reliability of digital tools even in processes requiring intensive monitoring like Phase 1.

Key strategic advantages offered by DCT models:

• Patient Diversity and Inclusivity: With the removal of geographical boundaries, access to individuals with rare diseases and minority groups becomes easier, increasing the generalizability of data.
• Rapid Patient Recruitment: While patient registration experiences an 80% delay with traditional methods, AI-supported DCT models can increase the registration speed by 10-20%.
• High Retention: Reduced travel burden and digital reminders significantly lower the dropout rates of volunteers from the trial.

Turkey’s Clinical Research Vision and TITCK Regulations

Turkey is in a “rising star” position in the global clinical research market with its strong health infrastructure and strategic geographical location. According to Association of Research-Based Pharmaceutical Companies (AIFD) data, clinical trial investments in Turkey reached nearly 520 million dollars in 2024, showing an increase of 69% compared to the previous year in TL terms, exceeding 17 billion TL. This growth proves that Turkey is not just a “data collection site” but also a center for qualified scientific research.

TITCK and Regulatory Updates: 2024-2025 Period

The Turkish Medicines and Medical Devices Agency (TITCK) is increasing Turkey’s attractiveness with regulatory steps aligned with international Good Clinical Practice (GCP) guidelines (ICH E6-R3). Specifically, the current guidelines published for Phase 1 centers have introduced strict and reassuring standards regarding the physical infrastructure, emergency intervention capacity, and laboratory integration of these centers.

MDR Transformation in Medical Device Clinical Trials

The world of clinical research is not limited to drugs. The Medical Device Regulation (MDR) that came into force in the European Union and Turkey has introduced much stricter clinical data requirements for device manufacturers. Especially for implants and high-risk devices in the Class III category, when an “equivalence” claim cannot be established, it has become mandatory for manufacturers to collect new clinical data (Clinical Investigation- CI) on their own devices.

MedicalPoint KAM offers critical support to medical device manufacturers in the following areas:

• Clinical Investigation Plan (CIP) Preparation: Protocol design suitable for MDR requirements and the device’s specific clinical objectives.
• Regulatory Compliance and Speed: Capacity to complete research in the shortest time with high data quality to overcome obstacles in the CE marking process.
• GCP Compliance: Conducting device trials under as rigorous ethical and scientific supervision as drug trials.

New Horizons in Oncology: ADCs, Bispecifics, and Smart Molecules

In the 2026 vision, oncology continues to be the locomotive of clinical research. 41% of global clinical trials are in the field of oncology. The most striking development in this field is that “next-generation modalities” such as Antibody-Drug Conjugates (ADC) and bispecific antibodies now cover 35% of total research.

Antibody-Drug Conjugates (ADC): Targeted Smart Bombs

ADCs are complex structures where a chemotherapy agent is transported directly to the cancer cell via an antibody. Phase 1 studies are vital in determining how the “toxin” load of these molecules will be released safely and how side effects will be managed. The ongoing ABBV-399 (Telisotuzumab Vedotin) study at MedicalPoint KAM is one of the most current examples of this technology.

ESMO 2025 and 2026: mRNA Vaccines and Immunotherapy Synergy

Data presented at the European Society for Medical Oncology (ESMO) Congress in October 2025 showed that mRNA-based COVID vaccines doubled survival rates in cancer patients treated with immune checkpoint inhibitors (immunotherapy). This “unexpected” observation triggered Phase 3 studies and opened the way for new combined treatment models in Phase 1. Such studies, managed by MD Anderson Kanser Merkezi, underline the dynamic nature of clinical trials and the importance of Real-World Evidence (RWE).

Safety, Ethics, and the Volunteering Principle in Clinical Research

Phase 1 trials are the most sensitive point of human health. Every trial conducted in centers like MedicalPoint is carried out in 100% compliance with the Declaration of Helsinki and TITCK regulations. The safety of volunteers is always prioritized over the scientific value of the trial.

Volunteering Process and Rights

The process for volunteers to be included in a study consists of the following steps:

1. Informing and Communication: Providing initial preliminary information about the study.
2. Face-to-Face Interview: Explanation of all risks and benefits by the researcher physician.
3. Informed Volunteer Consent Form (BGOF): The volunteer’s declaration that they understand the process and participate of their own free will.
4. Medical Evaluation: Comprehensive health screenings (Laboratory, imaging, physical examination).
5. Follow-up and Monitoring: Continuous monitoring by specialist doctors throughout the study period.

As an important note; in clinical trials, volunteers’ travel and meal expenses are covered by the sponsor, but no fee is paid for participation, nor is any fee requested from the volunteer. Volunteers have the right to leave the study at any time without giving any reason.

Future Projection: 2026-2030 Clinical Research Trends

The future of clinical research lies in the perfect harmony of technology with the human touch. Analyses by IQVIA and McKinsey predict that the following trends will dominate the sector in the next 5 years:

• Precision Medicine and Biomarker Focus: Phase 1 trials will now focus on customized dosages according to genetic profiles instead of “one dose fits all.”
• Data Integration and Cloud Computing: Secure cloud-based ecosystems where data from different centers merge in real-time will become standard.
• Financial Efficiency and AI: AI-supported cost savings are expected to account for 75% of the growth in the health market.
• Patient-Centricity: Trial designs will be structured in a way that does not disturb the patient’s quality of life (such as BYOD – Bring Your Own Device models).

Sectoral Trends and Expected Results

Conclusion

Clinical trials are the most advanced frontier of modern medicine, and Phase 1 studies are the gateway to this frontier. This field, where scientific curiosity merges with ethical responsibility and technological power with patient-centricity, promises a healthier future for humanity. Centers like MedicalPoint KAM, the pride of İzmir and Turkey, play a pioneering role on this sacred path with the high technology and expert academic staff they offer. As we progress toward 2026, every innovation from artificial intelligence to mRNA platforms will continue to be a ray of hope for “patients waiting for a cure.” Every support given to clinical research is, in fact, an investment humanity makes in its own future.

References

1. Global landscape of mRNA vaccine clinical trials: a systematic analysis of ClinicalTrials.gov data – Frontiers.
2. Trends for 2026: Targeted AI, continuous trials, and navigating uncertainty – Merative.
3. Top 10 Clinical Trial Trends 2026 | CTIP.
4. The AI revolution in clinical trials | PPD.
5. About Us – MedicalPoint Clinical Research Center.
6. Current landscape of clinical trials for mRNA-based therapeutics – PMC – NIH.
7. A Step‐by‐Step Workflow for Performing In Silico Clinical Trials With Nonlinear Mixed Effects Models – PMC.
8. In Silico Technologies: Leading the Future of Drug Development Breakthroughs.
9. From Lab to Clinic: How Artificial Intelligence (AI) Is Reshaping Drug Discovery Timelines and Industry Outcomes – PMC.
10. mRNA-Based Personalized Cancer Vaccines: Opportunities, Challenges and Outcomes.
11. Markey home to two breakthrough therapeutic cancer vaccine trials.
12. AI Applications in the Drug Development Pipeline | IntuitionLabs.
13. Unlocking peak operational performance in clinical development with artificial intelligence.
14. In silico clinical trials – Wikipedia.
15. Reimagining clinical trials with In Silico and AI-driven methods – ZS.
16. Case Study: Insilico’s Transformation.
17. Insilico Medicine announces developmental candidate benchmarks and timelines for novel therapeutics discovered using generative AI | EurekAlert!.
18. Decentralized clinical trials: A comprehensive analysis of trends, technologies, and global challenges – PMC.
19. Decentralized Clinical Trials in Early Drug Development—A Framework Proposal – PMC.
20. Decentralized Clinical Trials 2025 Industry Adoption Trends Report – CCRPS.
21. Decentralized Clinical Studies: Complete Guide 2025 | Curebase Resources.
22. The Digital Platform and Its Emerging Role in Decentralized Clinical Trials – Journal of Medical Internet Research.
23. Decentralized Clinical Trials in the Era of Real‐World Evidence: A Critical Assessment of Recent Experiences – PMC.
24. Decentralized Phase I Trial Highlights Promise of Remote Data Collection to Improve Clinical Research.
25. AIFD members’ total clinical trial investment in 2024.
26. TITCK Guideline on Phase 1 Clinical Trial Centers.
27. Phase 3 Clinical Trial – mphctc.
28. Clinical Research Association – New Phase I Center announcement.
29. Biruni University – Phase 1 Clinical Research Center Opening.
30. Medical Device Regulation (MDR) and Clinical Processes.
31. Global Oncology Trends 2025 | IQVIA.
32. Harnessing Innovation in Oncology: ASCO 2025 Insights.
33. ESMO 2025: mRNA-based COVID vaccines and immunotherapy – MD Anderson Cancer Center.
34. Global Medicine Use Trends 2026 | IQVIA.
35. AI-Enabled Multidisciplinary Oncology – ASCO Publications.
36. In Silico Clinical Trials: Improving drug development – American Statistical Association.